

20 February 2023

Nifty Intraday Chart



Market in Retrospect

Indian equity benchmarks declined at close after trading through volatility on Monday.

Nifty index ended 0.56% lower, ended at 17,845. The broader markets represented by the Nifty 500 Index ended 0.44% lower, ending at 14,939. Among the sectorial indices, Nifty IT was the top gainer gaining by 0.54%, followed by Nifty Auto gaining by 0.28%. Nifty PSU Bank was the top loser losing by 1.11%.

Divi's Lab was the top gainer, gaining by 2.50%, followed by Ultratech Cement and Tech Mahindra which gaining by 1.77% & 1.33%. Cipla was the top loser, losing by 6.02%, followed by Adani Enterprises and Britannia Industries losing by 5.88% & 1.75%.

Market Turnover (In Crore) 20-02-2023

Name	Last	Previous
NSE Cash	39466.91	41532.29
NSE F&O	15531174.53	12431797.90
BSE Cash	2,710.43	2,889.50
BSE F&O	*NA	122.15

FII Derivatives Flow (In Crore) 17-02-2023*

Instrument	Purchase	Sale	Net
Index Future	3916.55	4837.48	-920.93
Index Option	555276.34	557810.49	-2534.15
Stock Future	9891.99	10478.65	-586.66
Stock Option	11336.00	11474.77	-138.77

Institutional Flow (In Crore) 20-02-2023

Institution	Purchase	Sale	Net
FII	4256.62	4415.57	158.95
DII	4980.30	4894.07	86.23

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Divi'S Laboratories	2.50	4.59	740945	336403
Ultratech Cement	1.77	3.45	713498	476798
Tech Mahindra	1.33	14.13	4590531	6118179
Hindalco Industries	1.11	1.53	3749802	4461796
Power Grid Corp	0.94	0.09	5131438	4842387

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
UPL	1.58	3.29	1149759	3065745
BPCL	1.67	2.61	1773126	2371226
Britannia Industries	1.75	2.93	308681	198524
Adani Enterprises	5.88	5.60	6762330	9079515
Cipla	6.02	5.67	5829572	928353


Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 6:40PM



Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	60691.54	311.03	0.51	0.43	0.12	1.58	4.94
Nifty	17844.60	99.60	0.56	0.41	1.02	2.53	3.29
BSE M Cap	24656.08	29.19	0.12	0.31	1.40	1.91	3.72
BSE S Cap	28002.27	44.13	0.16	0.25	2.19	2.60	0.92
Nifty MC 100	30666.90	24.85	0.08	0.33	1.39	0.81	5.99
BSE Auto	30201.90	72.53	0.24	0.01	3.76	3.18	16.56
BSE Capgoods	35006.35	116.07	0.33	0.75	0.41	4.90	23.12
BSE FMCG	16405.56	45.11	0.27	0.02	2.77	3.01	22.42
BSE Metal	20452.37	0.65	0.00	2.08	5.85	3.26	1.36
BSE Oil&Gas	17441.75	196.78	1.12	0.24	16.88	11.81	3.53
BSE Healthcare	22143.26	116.06	0.52	0.67	3.09	5.39	7.09
BSE Power	3376.90	18.88	0.56	2.94	25.31	28.06	12.54
BSE Realty	3209.61	23.32	0.72	1.77	5.91	10.16	9.97
BSE ConsDur	38364.36	265.86	0.69	0.71	1.09	5.85	9.67
BSE Bank	46013.53	494.74	1.06	1.41	4.59	5.22	6.85
BSE IT	30951.90	157.02	0.51	2.65	5.05	3.81	9.55

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.81	0.00	0.00	3.06	9.66	0.37	97.80
UK	3.46	0.06	1.62	1.65	2.37	6.76	150.94
Brazil	6.48	0.03	0.45	1.89	12.28	3.45	26.42
Japan	0.51	0.00	0.39	1.17	30.83	102.81	133.80
Australia	3.81	0.01	0.26	1.33	12.10	5.48	69.52
India	7.35	0.02	0.23	0.08	0.08	0.63	10.37
Switzerland	1.43	0.01	0.90	0.99	21.03	38.32	434.70
Germany	2.43	0.01	0.53	2.49	11.48	20.51	1164.06

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.73	0.10	0.12	0.01	1.94	1.07	9.93
USD Index	103.89	0.02	0.02	0.52	1.84	2.85	8.17
YUAN	6.86	0.01	0.14	0.59	1.08	4.47	7.64
GBP	1.20	0.00	0.09	0.93	2.99	1.72	11.59
EUR	1.07	0.00	0.12	0.38	1.60	4.30	5.56
YEN	134.07	0.08	0.06	1.23	3.33	6.02	14.42

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	538.00	8.00	1.51	10.63	29.49	54.75	72.61
Baltic Dirty	1261.00	17.00	1.37	4.73	10.88	46.68	80.40
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33826.69	129.84	0.39	0.13	1.35	0.24	0.74
Nasdaq	11787.27	68.56	0.58	0.59	5.81	5.75	13.00
S&P 500	4079.09	11.32	0.28	0.28	2.68	2.87	6.20
FTSE100	8005.82	1.59	0.02	0.73	3.03	8.40	6.55
CAC40	7339.83	8.15	0.11	1.82	4.91	10.46	5.92
DAX	15483.31	0.02	0.00	0.55	2.98	7.28	2.92
Mexico IPC	53789.64	226.18	0.42	2.49	0.29	4.30	2.88
Brazil Bovespa	109176.9	764.54	0.70	1.02	2.56	0.28	3.28
Russian RTS	912.66	7.74	0.84	5.53	8.01	20.45	34.42
Japan Nikkei	27531.94	18.81	0.07	0.38	3.68	1.32	1.51
Hang Seng	20886.96	167.15	0.81	1.31	5.25	16.09	14.14
Taiwan Index	15551.23	71.53	0.46	0.04	4.14	7.21	14.71
Shanghai Comp	3290.34	66.31	2.06	0.19	0.78	6.23	5.74
KOSPI	2455.12	3.91	0.16	0.10	2.50	0.44	10.54
Malaysia KLCI	1473.46	3.44	0.23	0.12	1.79	1.67	8.08
Jakarta Comp	6894.72	1.00	0.01	0.08	0.29	2.65	0.03
Philippine SE	6744.12	34.90	0.51	1.38	4.43	4.76	9.09
Thai Exch	1657.69	6.02	0.36	0.43	1.17	2.49	3.24

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	76.68	0.34	0.45	4.32	5.69	4.25	15.80
BRENT Crude	83.49	0.41	0.49	3.69	4.87	2.93	1.76
Natural Gas	2.25	0.02	1.10	6.44	25.89	60.55	47.38

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1843.80	1.42	0.08	0.52	4.27	5.32	2.88
Silver(\$/Ounce)	21.72	0.01	0.07	1.26	9.26	3.70	9.22
Aluminium	2346.50	7.75	0.33	2.42	9.53	0.78	29.21
Copper	8950.25	41.25	0.46	1.38	3.58	10.88	10.34
Zinc	3085.75	55.00	1.81	0.85	6.85	3.41	14.93
Lead	2056.25	39.50	1.96	0.60	8.16	3.87	12.88

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	185.75	5.50	3.05	6.36	22.36	18.31	22.20
Cotton	81.50	0.50	0.61	4.77	1.90	3.42	15.16
Sugar	19.80	0.03	0.15	1.20	5.43	6.34	12.95
Wheat	776.25	0.00	0.00	2.45	2.27	7.06	3.30
Soybean	1522.25	1.00	0.07	0.73	0.99	6.56	7.33

Gland Pharma to invest Rs 400 crore to expand its Telangana plant

Gland Pharma announced that it would be investing Rs 400 crore to create additional capabilities in its existing facility at Genome Valley here to manufacture biologicals, biosimilar, antibodies and recombinant Insulin. An official release from the state government said the expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places. The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others. The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines. The announcement was made after Telangana Industries Minister KT Rama Rao's meeting with the Managing Director and Chief Executive Officer of Gland Pharma Srinivas Sadu.

Centre opposes Hindustan Zinc's \$2.98 billion deal for Vedanta zinc assets

India's federal government has opposed Hindustan Zinc's proposed \$2.98 billion acquisition of zinc assets from Vedanta Ltd, a letter from the government to the company showed on Monday. The government will oppose any further resolutions on the deal and explore all legal avenues available to it. Directors nominated by the government at Hindustan Zinc had dissented to the proposed deal announced on Jan. 19, the letter showed. The notice calling the shareholders meeting has not been issued so far, it adds. The company will place the ministry's letter before the Board in the ensuing meeting for its consideration. The government holds a near 30% stake in Hindustan Zinc, while Vedanta is the company's largest shareholder.

Tata Motors to supply 25,000 XPRES-T electric sedans to Uber

Tata Motors on Monday said it will supply 25,000 XPRES-T electric vehicle units to Uber in one of the largest deals in the green mobility space till date. As per a memorandum of understanding inked between the two entities, Uber will utilise the electric sedans in its premium category service. The electric fleet would be operational across Delhi NCR, Mumbai, Kolkata, Chennai, Hyderabad, Bengaluru and Ahmedabad. The Mumbai-based automaker will begin the deliveries of the cars to Uber fleet partners in a phased manner, starting this month. The companies did not provide the financial details of the deal.

CEF Group to invest Rs 650 crore in Uttar Pradesh for biofuel production

Energy solutions company, CEF Group has signed an MoU with the government of Uttar Pradesh to set up multiple waste processing plants in various locations in UP to address the problem of waste mismanagement and augment bio-fuel production. The group will invest Rs 650 crore in setting up the plants, generating employment for approximately 240 people.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
DISA India Ltd	Cash dividend of INR100 effective 21-02-2023
Akzo Nobel India Ltd	Cash dividend of INR25 effective 21-02-2023
Cummins India Ltd	Cash dividend of INR12 effective 21-02-2023
IndInfravit Trust	Cash dividend of INR4.20 effective 21-02-2023
MRF Ltd	Cash dividend of INR3 effective 21-02-2023
Natco Pharma Ltd	Cash dividend of INR1.25 effective 21-02-2023
Anzen India Energy Yield Plus Trust	Cash dividend of INR1.24 effective 21-02-2023
ASM Technologies Ltd	Cash dividend of INR1 effective 21-02-2023
Oracle Credit Ltd	Cash dividend of INR0.50 effective 21-02-2023
AVT Natural Products Ltd	Cash dividend of INR0.40 effective 21-02-2023
ASM Technologies Ltd	Cash dividend of INR0.30 effective 21-02-2023
Sat Industries Ltd	Cash dividend of INR0.10 effective 21-02-2023
Vishwaraj Sugar Industries Ltd	Cash dividend of INR0.10 effective 21-02-2023
Shree Securities Ltd	Corporate meeting effective 21-02-2023

Domestic Events

- No events

Global Events

- Japan Jibun Bank Flash PMI for February 2023.
- The U.S. S&P Global Flash PMI for February 2023.
- The U.S. Existing Home Sales for January 2023.
- Euro Area S&P Global Flash PMI for February 2023.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
